Yufeng Huang

Yufeng Huang, MD, PhD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine

Divisions: Nephrology & Hypertension

Academic Office Information

Yufeng.Huang@hsc.utah.edu

Research Interests

  • Antifibrotic PAI-1
  • Renal Fibrosis
  • Diabetic Nephropathy
  • Renin-Angiotensin System
  • Non-Viral Gene Delivery

Yufeng Huang, MD, Ph.D, is a research associate professor in the department of Medicine, Division of Nephrology at the University of Utah School of Medicine. As a basic and translational researcher, her research interests include roles of TGFß, PAI-1 and the renin, angiotensin and aldosterone system in promoting renal fibrosis in kidney disease.

Huang received her medical degree and completed her residency at the Jiangsu University in China. She continuously completed her fellowship in Nephrology and received her Ph.D degree at the Fudan University, Shanghai Medical College in China.

Research Statement

My research focuses on the pathophysiological role of receptor-mediated prorenin/renin's actions in renal fibrosis and the non-viral strategies for cell-specific delivery of pathway-interactors and molecular probles to diseased kidneys.

Education History

Postdoctoral Fellowship University of Utah School of Medicine
 Postdoctoral Fellow
Doctoral Training Fudan University Shanghai Medical College
 PhD
Fellowship Shanghai Medical College, Fudan University
 Fellow
Residency Zhenjiang Medical College Hospital, Jiangsu University
 Resident
Internship Zhenjiang Medical College
 Intern
Professional Medical Zhenjiang Medical College, Jiangsu University
 MD

Selected Publications

Journal Article

  1. Tian M, Carroll LS, Tang L, Uehara H, Westenfelder C, Ambati BK, and Huang Y (2020). Systemic AAV10.COMP-Ang1 rescues renal glomeruli and pancreatic islets in type 2 diabetic mice. BMJ Open Diabetes Res Care, 8(1), e000882.
  2. Liu S, Huang Z, Tang A, Wu X, Aube J, Xu L, Xing C and Huang Y (2020). Inhibition of RNA-binding protein HuR reduces glomerulosclerosis in experimental nephritis. Clin Sci (Lond), 134, 1433-1448.
  3. Zhang Y, Hansson KM, Liu T, Magnell K, Huang Y, Carlson NG, Kishore BK (2018). Genetic Deletion of ADP-activated P2Y12 Receptor Ameliorates Lithium-induced Nephrogenic Diabetes Insipidus in Mice. Acta Physiol (Oxf), 225, e13191.
  4. Conlin CC, Huang Y, Gordon BAJ, Zhang JL (2018). Quantitative characterization of glomerular fibrosis with magnetic resonance imaging. A feasibility study in a rat glomerulonephritis model. 314, F747-F752.
  5. Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, Geschwindner S, Aagaard A, Granqvist AB, Jaisser F, Huang Y, Granberg KL, Jansson-Lofmark R, Hartleib-Geschwindner J (2018). Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One, 13(2), E0193380.
  6. Zhou G, Wu J, Gu C, Wang B, Abel ED, Cheung AK, and Huang Y (2018). Prorenin independently causes hypertension and renal and cardiac fibrosis in cyp1a1 prorenin transgenic rats. Clin Sci (Lond), 132, 1345-1363.
  7. Tian M, Tang L, Wu Y, Beddhu S, Huang Y (2018). Adiponectin attenuates kidney injury and fibrosis in Deoxycorticosterone Acetate-Salt and Angiotensin II-induced CKD mice.
  8. Conlin CC, Oesingmann N, Bolster Jr B Huang Y, Lee VS, and Zhang JL (2016). Renal plasma flow (RPF) measured with multiple-inversion-time arterial spin labeling (ASL) and tracer kinetic analysis: Validation against a dynamic contrast enhancement method. Magn Reson Imaging, 37, 51-55.
  9. Tang L, Wu Y, Tian M, Sjostrom CD, Johansson U, Peng XR, Smith DM and Huang Y (2017). Dapagliflozin slows the progression of the renal and liver fiboriss associated with type 2 diabetes. Am J Physiol Endocrinol Metab, 313(5), E563-E576.
  10. Hwang J, Huang Y, Burwell TJ, Peterson NC, Connor J, Weiss SJ, Yu SM, Li Y (2017). In situ imaging of tissue remodeling with collagen hybridizing peptides. ACS Nano, 11, 9825-9835.
  11. Klein J, Ramirez-Torres A, Ericsson A, Huang Y, Breuil B, Siwy J, Mischak H, Peng XR, Bascands JL, Schanstra JP (2016). Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney Int, 90, 1045-1055.
  12. Gu C, Zhang J, Noble NA, Peng XR, Huang Y (2016). An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease. 311, F852- F863.
  13. Zhou G, Johansson U, Peng XR, Bamberg K, Huang Y (03/15/2016). An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am J Transl Res, 8(3), 1339-54.
  14. Beddhu S, Filipowicz R, Wang B, Wei G, Cheng X, Roy AC, Duvall S, Farrukh H, Habib A, Bjhordahl T, Simmons D, Munger M, Stoddard G, Kohan D, Greene T and Huang Y (2016). A randomized controlled trial of the effects of febuxostat therapy on adiokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Can J Kidney Health Dis, 3, 1-11.
  15. Conlin CC, Oesingmann N, Bolster Jr B, Huang Y, Lee VS, Zhang JL (2016). Renal plasma flow (RPF) measured with multiple-inversion-time arterial spin labeling (ASL) and tracer kinetic analysis: Validation against a dynamic contrast enhancement method. Magn Reson Imaging, (37), 51-55.
  16. Zhou G, Liu X, Cheung AK, Huang Y (2015). Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus? Am J Transl Res, 7(5), 825-40.
  17. Gu C, Noble NA, Border WA, Cheung AK and Huang Y (2014). Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocyte. J Renin Angiotensin Aldosterone Syst, 15, 177-189.
  18. Zhang J, Gu C, Lawrence DA, Cheung AK and Huang Y (2014). A PAI-1 mutant retards diabetic nephropathy in db/db mice through protecting podocytes. Exp Physiol, 99, 802-815.
  19. Guo X, Zhou G, Guo M, Cheung AK, Huang Y and Beddhu S (2014). Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II. Physiol Res, 2, e00230.
  20. Zhou G, Cheung AK, Liu X and Huang Y (2013). Valsartan slows the progression of diabetic nephropathy in db/db mice via reduction in podocyte injury and renal oxidative stress and inflammation. Clin Sci (Lond), 126, 707-720.
  21. Zhang J, Wu J, Gu C, Noble NA, Border WA and Huang Y (2012). Receptor-mediated non-proteolytic activation of prorenin and induction of TGFß1 and PAI-1 expression in renal mesangial cells. 303, F11-20.
  22. Zhang J, Gu C, Noble NA, Border WA and Huang Y (2011). Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. 301, F723-732.
  23. Zhang J, Noble NA, Border WA and Huang Y (2010). infusion of angiotensin-(1-7) reduces glomerulosclerosis in anti-thy 1 glomerulonephritis. 298, F579-588.
  24. Huang Y, Border WA, Lawrence DA, Noble NA (2009). Mechanisms underlying the anti-fibrotic properties of non-inhibitory PAI-1 (PAI-1R) in experimental nephritis. on line.
  25. Ge Y, Huang Y, Kohan DE (2008). Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure. Can J Physiol Pharmacol, 2008(86), 329-336.
  26. Zhang J, Noble NA, Border WA and Huang Y corresponding author (2008). Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. Am J Physiol Endocrinol Metab, 295, E810-E819.
  27. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA and Noble NA (2008). A non-inhibitory PAI-1 retards the progression of diabetic nephropathy in db/db mice. J Am Soc Nephrol, 2008(86), 329-336.
  28. Huang W, Xu C, Kahng K, Noble NA, Border WA and Huang Y corresponding author (2008). Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. 2008(294), F1287-1295.
  29. Huang Y, Noble NA, Zhang J, Xu C, Border WA (2007). Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int, 72(1), 45-52.
  30. Huang Y, Border WA, Lawrence DA, Noble NA (2006). Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int, 70(3), 515.
  31. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA and Border WA (2006). Renin increases mesangial cell transforming growth factor-ß1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int, 69(1), 105.
  32. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA (2004). Combining TGFß inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int, 66, 1774.
  33. Li ZP, Xu X, Huang YF, Zhu JF, Wang XJ, Hu HH, He ZP (2003). Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor for occurrence of diabetic retinopathy (Chinese). Zhonghua Yan Ke Za Zhi, 39(6), 352-6.
  34. Huang Y, Haraguchi M, Lawrence DA, Border WA, Noble NA (2003). A mutant, non-inhibitory plasminogen activator inhibitor-type 1 (PAI-1) decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest, 112, 337-388.
  35. Yu L, Border WA, Huang Y, Noble NA (2003). TGFß isoforms and renal fibrogenesis. Kidney Int, 64, 844-856.
  36. Xu X, Li Z, Luo D, Huang Y, Zhu J, Wang X, Hu H, Patrick CP (2003). Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol, 241(1), 56-62.
  37. Haraguchi M, Border WA, Huang Y, Noble NA (2001). t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int, 59, 2146-2155.
  38. Huang Y, Shanyan L, Jianghua Z (1998). Gene expression of receptor for advanced glycation end products and its modulation by Aminoguanidine in diabetic kidney tissue. Chin Med J (Engl), 111 (8), 698.

Review

  1. Huang Y, Noble NA (2007). PAI-1 as a Target in Kidney Disease. [Review]. Curr Drug Targets, 8(9), 1007-15.
  2. Huang Y, Border WA, Noble NA (2007). Functional Renin Receptors in Renal Mesangial Cells. [Review]. Curr Hypertens Rep, 9(2), 133-139.

Editorial

  1. Huang Y, Border WA and Noble NA (2006). Perspectives on blockade of TGF-ß overexpression. Kidney Int, 69(10), 1713.
  2. Yufeng Huang, Nancy A Noble (2005). An unexpected role of plasminogen activator inhibitor-type 1 (PAI-1) in renal fibrosis. Kidney Int, 67, 2502.